Vernal Biosciences
Signal active
Organization
Contact Information
Overview
Vernal Biosciences specializes in high-purity mRNA for research and clinical use. Its platform processes and analytical methods will remove the guesswork and lengthy development cycles inherent to many manufacturing processes in the advanced therapeutics field. Its high-purity supply and services provide the flexibility to perform proper drug discovery and development without risking the buildout of costly teams and facilities.
About
Industries
Biotechnology, Life Science, Medical
Founded
2021
Employees
51-100
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Vernal Biosciences headquartered in United States, North America, operates in the Biotechnology, Life Science, Medical sector. The company focuses on Biotechnology and has secured $1.5B in funding across 36 round(s). With a team of 51-100 employees, Vernal Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Vernal Biosciences, raised $20.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
4
Lead Investors
0
Total Funding Amount
$41.0M
Details
3
Vernal Biosciences has raised a total of $41.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Seed | |||
| 2022 | Early Stage Venture | 21.0M | ||
| 2023 | Early Stage Venture | 20.0M |
Investors
Vernal Biosciences is funded by 24 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Dynamk Capital | - | FUNDING ROUND - Dynamk Capital | 20.0M |
| David Q. Anderson | - | FUNDING ROUND - David Q. Anderson | 20.0M |
| Vernal Biosciences | - | FUNDING ROUND - Vernal Biosciences | 20.0M |
| Ampersand Capital Partners | - | FUNDING ROUND - Ampersand Capital Partners | 20.0M |
Recent Activity
There is no recent news or activity for this profile.